nih glp 1 Frontiers The expanding scope of GLP-1
Description
and Eisai
Key Segment Analysis 20.2
Karakasis P, et al
Klinic ensures you receive FDA-approved options like Zepbound
In 2022, after it was approved for Type 2 diabetes, spending on Mounjaro grew rapidly to $2.51 billion
Less common but important: gallbladder issues, dehydration, and rare reports of pancreatitis
